SETDB2 and neoplasm: To further determine whether SETDB2 silencing decreases the number of tumor initiating cells (cancer stem cells), we performed an extreme limiting dilution analysis (ELDA) 25 and found that silencing SETDB2 decreased the breast cancer stem cell frequency from 1 in 1,439 to 1 in 185,086 (sh S-3) or 1 in 1,242,886 (sh S-4), which represents a 128-fold (sh S-3) and a 863-fold (sh S-4) decrease (p=1.82×10-16) (Figure 3D and 3E).